RTP Mobile Logo

Interview with Philip A Philip, MD, PhD

Track 1: Case: A 72-year-old man with locally advanced, unresectable adenocarcinoma of the pancreas receives neoadjuvant gemcitabine/nanoparticle albumin-bound (nab) paclitaxel
Track 2: Choosing between neoadjuvant gemcitabine/nab paclitaxel and FOLFIRINOX
Track 3: SWOG-S1505: An ongoing Phase II trial of perioperative modified FOLFIRINOX versus gemcitabine/nab paclitaxel for resectable adenocarcinoma of the pancreas
Track 4: Activity and tolerability of concurrent capecitabine and radiation therapy
Track 5: Therapeutic options for patients with metastatic pancreatic cancer who experience disease progression on a gemcitabine-based regimen
Track 6: Formulation and risk-benefit ratio of nanoliposomal irinotecan (nal-IRI) versus standard IV irinotecan
Track 7: Discussing prognosis and goals of therapy with patients with relapsed/refractory metastatic pancreatic cancer
Track 8: Finding meaning and satisfaction as an oncologist
Track 9: Case: An 84-year-old man with metastatic pancreatic cancer receives nal-IRI and 5-FU/leucovorin (LV) after disease progression on gemcitabine/nab paclitaxel
Track 10: Dose-modified gemcitabine/nab paclitaxel for elderly patients with metastatic disease
Track 11: Importance of supportive care for patients with terminal cancer
Track 12: Efficacy of nal-IRI/5-FU/LV for patients with recurrent pancreatic cancer and liver metastases
Track 13: Case: A 57-year-old man with invasive, moderately differentiated adenocarcinoma of the pancreas receives adjuvant gemcitabine/capecitabine
Track 14: Clinical experience with and dosing of adjuvant gemcitabine/capecitabine
Track 15: Ongoing trials evaluating adjuvant chemotherapy with and without radiation therapy
Track 16: Case: A 51-year-old man with a strong family history of BRCA-related cancer presents with Stage IV pancreatic cancer with liver metastases and is found to harbor a germline BRCA mutation
Track 17: Potential role of platinum-based chemotherapy in combination with a PARP inhibitor for BRCA mutation-positive metastatic pancreatic cancer
Track 18: SWOG-S1513: An ongoing Phase II trial of FOLFIRI alone versus modified FOLFIRI with the PARP inhibitor veliparib as second-line therapy for metastatic pancreatic cancer
Track 19: Activity of PARP inhibitors in BRCA germline mutation-positive pancreatic cancer; incidence of and screening for BRCA mutations
Track 20: Novel pathways and strategies under investigation in pancreatic cancer
Track 21: Targeting tumor stroma with the pegylated recombinant human hyaluronidase enzyme PEGPH20; mitigation of associated thromboembolic events
Track 22: Tolerability of the cancer stemness inhibitor napabucasin in patients with pancreatic cancer
Track 23: Immune checkpoint inhibitors for pancreatic cancer
Track 24: Efficacy of first-line treatment options for metastatic pancreatic cancer
Track 25: Response and tolerability of FOLFIRINOX compared to gemcitabine/nab paclitaxel
Track 26: Second-line therapy options for metastatic pancreatic cancer

Interview with Ramesh K Ramanathan, MD

Track 1: ASCO Clinical Practice Guidelines for metastatic pancreatic cancer
Track 2: Genomic drivers in pancreatic ductal adenocarcinoma
Track 3: Significance of BRCA germline and somatic mutations in pancreatic cancer
Track 4: Testing for microsatellite instability in patients with metastatic pancreatic cancer
Track 5: Ongoing Phase II trial of nivolumab/nab paclitaxel/paricalcitol/cisplatin/gemcitabine for previously untreated metastatic pancreatic ductal adenocarcinoma
Track 6: Activity of PEGPH20 in combination with gemcitabine/nab paclitaxel or FOLFIRINOX for metastatic pancreatic ductal adenocarcinoma
Track 7: Tumor reduction in primary and metastatic pancreatic cancer with gemcitabine/nab paclitaxel
Track 8: Biologic rationale for the superior activity of nab paclitaxel compared to standard-formulation paclitaxel
Track 9: Nomogram for predicting overall survival among patients with metastatic pancreatic cancer treated with gemcitabine alone or in combination with nab paclitaxel
Track 10: SEENA-1: Results of a Phase II trial of gemcitabine/nab paclitaxel followed by sequential modified FOLFIRINOX or alternating with modified FOLFIRI for untreated metastatic pancreatic cancer
Track 11: Potential use of maintenance therapy for pancreatic cancer
Track 12: Activity of gemcitabine/nab paclitaxel with cisplatin in patients with Stage IV pancreatic cancer
Track 13: Second-line therapy options for pancreatic ductal adenocarcinoma
Track 14: Correlation between MRI-detected ferumoxytol uptake in tumor lesions and response to nal-IRI
Track 15: Case: A 63-year-old woman presents with obstructive jaundice, is diagnosed with borderline-resectable pancreatic cancer and receives neoadjuvant modified FOLFIRINOX
Track 16: Clinical experience with adjuvant gemcitabine/capecitabine
Track 17: Case: A 74-year-old man with metastatic pancreatic cancer receives first-line gemcitabine/nab paclitaxel and second-line nal-IRI
Track 18: Importance of palliative care in managing the formidable symptoms of pancreatic cancer
Track 19: Case: A 74-year-old woman presents with an isolated lung lesion 3 years after undergoing a pancreatic tail resection for a T2N0 adenocarcinoma
Track 20: Case: A 51-year-old woman with a family history of breast and ovarian cancer is diagnosed with metastatic pancreatic cancer and undergoes BRCA testing
Philip A Philip, MD, PhD
Professor of Oncology and Pharmacology
Director of GI and Neuroendocrine Tumors
Vice President of Medical Affairs
Karmanos Cancer Institute
Wayne State University
Detroit, Michigan
Ramesh K Ramanathan, MD
Professor of Medicine
Mayo Clinic College of Medicine
Director, GI Medical Oncology
Mayo Clinic, Arizona
Associate Director, Early Cancer Therapeutics Program
Mayo Clinic Cancer Center
Scottsdale, Arizona
Neil Love, MD
Research To Practice
Miami, Florida